Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Prodromal Parkinson’s disease: identification & ethical issues

Gennaro Pagano, MD, MSc, PhD, F. Hoffmann – La Roche Ltd, Basel, Switzerland, outlines the importance of considering the Parkinson’s disease prodrome when developing novel therapies. Future clinical trials will start to include patients in the prodromal phase of the disease; however, numerous challenges are associated with targeting the prodrome, such as identifying the patients and sharing their status with them when no treatments are available. Investigations on how to best inform the patients and their families about their prodromal status are underway. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.